Systematic review of levodopa dose equivalency reporting in Parkinson's disease.
Interpretation of clinical trials comparing different drug regimens for Parkinson's disease (PD) is complicated by the different dose intensities used: higher doses of levodopa and, possibly, other drugs produce better symptomatic control but more late complications. To address this problem, conversion factors have been calculated for antiparkinsonian drugs that yield a total daily levodopa equivalent dose (LED). LED estimates vary, so we undertook a systematic review of studies reporting LEDs to provide standardized formulae. Electronic database and hand searching of references identified 56 primary reports of LED estimates. Data were extracted and the mean and modal LEDs calculated. This yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale. Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications.
Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, United Kingdom. c.l.tomlinson@adf.bham.ac.uk
Claire L
CL
Tomlinson
Rebecca
R
Stowe
Smitaa
S
Patel
Caroline
C
Rick
Richard
R
Gray
Carl E
CE
Clarke
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007980:Levodopa